Search

Your search keyword '"Rowley, A."' showing total 6 results
Start Over Author "Rowley, A." Language italian
6 results on '"Rowley, A."'

1. The Case of W.B. Yeats: Mind, Nation and Literary Landscape

Author

Rosemarie Rowley

Subjects
Geography. Anthropology. Recreation, Environmental sciences, GE1-350
Abstract

The emergence of the nation states was one of the fruits of Romanticism,and each reborn country needed to rediscover its identity: in Ireland, identitywas very much tied to the landscape and what remained of the Irish language,place-names playing a special role in the evocation of national desires.A study of these key texts of Yeats’ shows how his dedication to the life ofthe mind mirrored the loss of contact with the natural world. This is true of itslandscapes and its mythological figures. I hope to show that in an early poem“The Song of Wandering Aengus” that in developing an antithetical self, Yeatswas at significant times not only opposed to Nature intellectually andspiritually, but also emotionally. The privileging of the life of the mind over theanimal self has played in his own life and in his influence what may have been acostly division.

Published
2011

5. Liguria: aperture e chiusure di un'isola fra due pianure

Author

Maggi, Roberto, Binder, Didier, Panelli, Chiara, Gabriele, Marzia, Pearce, Mark, Rossi, Stefano, Rowley-Conwy, Peter, Culture et Environnements, Préhistoire, Antiquité, Moyen-Age (CEPAM), Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)

Subjects
ComputingMilieux_MISCELLANEOUS, [SHS]Humanities and Social Sciences
Abstract

International audience

Published
2020

6. Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-​Integrase Inhibitor for the Treatment of HIV-​AIDS Infection

Author

Summa V, Petrocchi, Alessia, Bonelli, Fabio, Crescenzi, Benedetta, Donghi, Monica, Ferrara, Marco, Fiore, Fabrizio, Gardelli, Cristina, Gonzalez Paz, Odalys, Hazuda, Daria J., Jones, Philip, Kinzel, Olaf, Laufer, Ralph, Monteagudo, Edith, Muraglia, Ester, Nizi, Emanuela, Orvieto, Federica, Pace, Paola, Pescatore, Giovanna, Scarpelli, Rita, Stillmock, Kara, Witmer, Marc V., Rowley, Michael, Summa, V, Petrocchi, Alessia, Bonelli, Fabio, Crescenzi, Benedetta, Donghi, Monica, Ferrara, Marco, Fiore, Fabrizio, Gardelli, Cristina, Gonzalez, Paz, Odalys, Hazuda, Daria, J., Jones, Philip, Kinzel, Olaf, Laufer, Ralph, Monteagudo, Edith, Muraglia, Ester, Nizi, Emanuela, Orvieto, Federica, Pace, Paola, Pescatore, Giovanna, Scarpelli, Rita, Stillmock, Kara, Witmer, Marc, V., Rowley, and Michael

Subjects
Magnetic Resonance Spectroscopy, Administration, Oral, Biological Availability, Phases of clinical research, Integrase inhibitor, HIV Infections, Biology, Mass Spectrometry, Virus, Raltegravir Potassium, Acquired immunodeficiency syndrome (AIDS), Drug Discovery, medicine, Humans, HIV Integrase Inhibitors, virus diseases, medicine.disease, Raltegravir, biology.organism_classification, Virology, Pyrrolidinones, Integrase, Area Under Curve, Lentivirus, biology.protein, Molecular Medicine, Half-Life, medicine.drug
Abstract

Human immunodeficiency virus type-1 (HIV-1) integrase is one of the three virally encoded enzymes required for replication and therefore a rational target for chemotherapeutic intervention in the treatment of HIV-1 infection. We report here the discovery of Raltegravir, the first HIV-integrase inhibitor approved by FDA for the treatment of HIV infection. It derives from the evolution of 5,6-dihydroxypyrimidine-4-carboxamides and N-methyl-4-hydroxypyrimidinone-carboxamides, which exhibited potent inhibition of the HIV-integrase catalyzed strand transfer process. Structural modifications on these molecules were made in order to maximize potency as HIV-integrase inhibitors against the wild type virus, a selection of mutants, and optimize the selectivity, pharmacokinetic, and metabolic profiles in preclinical species. The good profile of Raltegravir has enabled its progression toward the end of phase III clinical trials for the treatment of HIV-1 infection and culminated with the FDA approval as the first HIV-integrase inhibitor for the treatment of HIV-1 infection.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results